LON:EVG Evgen Pharma (EVG) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Evgen Pharma Stock (LON:EVG) Get Evgen Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume227,410 shsAverage Volume1.73 million shsMarket Capitalization£3.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom. Read More Receive EVG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evgen Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVG Stock News HeadlinesMetastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsightApril 30, 2025 | finance.yahoo.comBreast Cancer Market to Witness Upsurge in Growth by 2032, According to DelveInsightMarch 27, 2025 | theglobeandmail.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 26 at 1:00 AM | Porter & Company (Ad)TheraCryf Reports Positive SFX-01 Study ResultsNovember 11, 2024 | markets.businessinsider.comPassing of Dr Sue Foden, ChairNovember 6, 2024 | lse.co.ukPROTAC Market is Expected to Showcase Significant Growth During the Study Period (2020–2034) | DelveInsightAugust 12, 2024 | finance.yahoo.comGlobal Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsightAugust 1, 2024 | finance.yahoo.comTRADING UPDATES: Northcoders launches bootcamp; Schroder investsApril 4, 2024 | lse.co.ukSee More Headlines EVG Stock Analysis - Frequently Asked Questions How were Evgen Pharma's earnings last quarter? Evgen Pharma plc (LON:EVG) released its quarterly earnings results on Monday, June, 15th. The company reported ($2.10) earnings per share for the quarter, meeting the consensus estimate of ($2.10). How do I buy shares of Evgen Pharma? Shares of EVG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Evgen Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evgen Pharma investors own include genedrive (GDR), B&M European Value Retail (BME), Capital & Counties Properties PLC (CAPC), Coats Group (COA), 4D pharma (DDDD) and Greencore Group (GNC). Company Calendar Last Earnings6/15/2020Today8/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorFinance Industry Financial Services Sub-IndustryDiversified Financial Services Current SymbolLON:EVG CIKN/A Webevgen.com Phone+44-151-7053532FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£3.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-60.57% Return on Assets-45.52% Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio23.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow1.71 Book ValueGBX 1 per share Price / BookN/AMiscellaneous Outstanding Shares427,350,000Free FloatN/AMarket Cap£3.42 million OptionableNot Optionable Beta1.44 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (LON:EVG) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLook at this $5 stock’s addressA small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...Freedom Financial | SponsoredTrump’s new dollar decreeThe last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...Porter & Company | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evgen Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Evgen Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
